Vaccination contre le rotavirus : pour qui, pourquoi ?

Tuerlinckx, David
(2006) Louvain médical — Vol. 125, n° 9, p. S333-S336 (2006)

Files

137224.pdf
  • Restricted Access
  • Adobe PDF
  • 2.56 MB
Request a copy

Details

Authors
Abstract
[Anti-rotavirus vaccination: For which, why?]Rotavirus disease kills approximately half a million children annually and accounts for one third of hospitalisations for gastro-enteritis. The rotavirus vaccine is the hopeful way to control the disease burden. The main objectives of all new vaccines are safety and efficacy. Two manufacturers have accepted the challenge to develop a new live oral rotavirus vaccine. Efficacy and safety of these new vaccines is based on large-scale trials. Both vaccines demonstrate an impressive efficacy profile with a particularly great reduction in hospitalisations for gastro-enteritis. They demonstrate also a reassuring safety profile. With the introduction of rotavirus vaccine, we should expect to see a substantial reduction in direct and indirect costs due to rotavirus infection as well as an effect on mortality in developing countries.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Tuerlinckx, D. (2006). Vaccination contre le rotavirus : pour qui, pourquoi ? Louvain médical, 125(9), S333-S336. https://hdl.handle.net/2078.5/202850 (Original work published 2006)